

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of)

Mitchell E. REFF et al)

Serial No.: 09/019,441)

Filed: February 5, 1998)

For: GAMMA-1 AND GAMMA-3)
ANTI-HUMAN CD23)
MONOCLONAL ANTIBODIES)
AND USE THEREOF AS)
THERAPEUTICS)



Group Art Unit: 1644

Examiner: M. Dibrino

ATTENTION: BOX SEQUENCE

DECLARATION PURSUANT TO
37 C.F.R. §§1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Robin L. Teskin, declare as follows:

1. That the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same in compliance with §1.821(f).
2. That the submission, filed in accordance with 37 C.F.R. §1.821(g)[or (h)], herein does not include new matter [or go beyond the disclosure in the international application].

RECEIVED

JUL 31 2000
TECH CENTER 1600/2900

RECEIVED

JUL 28 2000
TECH CENTER 1600/2900

Serial No.: 09/019,441

3. That the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), is identical to that originally filed.

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

July 25, 2000

Date



Robin L. Teskin
Registration No. 35,030